Morgan Stanley
NERV icon

Morgan Stanley’s Minerva Neurosciences NERV Stock Holding History

Morgan Stanley’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$147K Buy
24,332
+13,277
+120% +$76.2K ﹤0.01% 5998
2025
Q4 		$44.4K Buy
11,055
+47
+0.4% +$175 ﹤0.01% 6476
2025
Q3 		$23.2K Hold
11,008
– – ﹤0.01% 6642
2025
Q2 		$18.9K Buy
11,008
+4
+0% +$7 ﹤0.01% 6664
2025
Q1 		$18.7K Sell
11,004
-5,100
-32% -$10.1K ﹤0.01% 6597
2024
Q4 		$35.8K Buy
16,104
+5,357
+50% +$12.6K ﹤0.01% 6392
2024
Q3 		$28.7K Hold
10,747
– – ﹤0.01% 6387
2024
Q2 		$34.3K Hold
10,747
– – ﹤0.01% 6288
2024
Q1 		$27.7K Sell
10,747
-1,825
-15% -$11.2K ﹤0.01% 6400
2023
Q4 		$77.3K Sell
12,572
-1,033
-8% -$5.91K ﹤0.01% 6244
2023
Q3 		$93.9K Buy
13,605
+4,610
+51% +$41.3K ﹤0.01% 5922
2023
Q2 		$82.2K Buy
8,995
+420
+5% +$2.22K ﹤0.01% 6028
2023
Q1 		$13.7K Sell
8,575
-100
-1% -$207 ﹤0.01% 6768
2022
Q4 		$13.8K Sell
8,675
-4,944
-36% -$21.4K ﹤0.01% 6823
2022
Q3 		$126K Buy
13,619
+6,627
+95% +$39.3K ﹤0.01% 5966
2022
Q2 		$23K Buy
6,992
+19
+0.3% +$78 ﹤0.01% 6925
2022
Q1 		$46K Sell
6,973
-25,825
-79% -$158K ﹤0.01% 6748
2021
Q4 		$210K Sell
32,798
-1,081
-3% -$10.2K ﹤0.01% 6037
2021
Q3 		$471K Sell
33,879
-45,262
-57% -$681K ﹤0.01% 5536
2021
Q2 		$1.47M Sell
79,141
-37,006
-32% -$797K ﹤0.01% 4856
2021
Q1 		$2.71M Buy
116,147
+55,731
+92% +$1.39M ﹤0.01% 4016
2020
Q4 		$1.13M Buy
60,416
+59,675
+8,053% +$1.5M ﹤0.01% 4585
2020
Q3 		$19K Sell
741
-901
-55% -$24.4K ﹤0.01% 6091
2020
Q2 		$47K Buy
1,642
+804
+96% +$47.2K ﹤0.01% 5691
2020
Q1 		$40K Sell
838
-4,564
-84% -$275K ﹤0.01% 5555
2019
Q4 		$307K Buy
5,402
+3,436
+175% +$152K ﹤0.01% 5200
2019
Q3 		$121K Buy
1,966
+1,328
+208% +$75.2K ﹤0.01% 5370
2019
Q2 		$29K Sell
638
-297
-32% -$14.9K ﹤0.01% 5816
2019
Q1 		$59K Sell
935
-18,388
-95% -$1.11M ﹤0.01% 5597
2018
Q4 		$1.04M Buy
19,323
+11,836
+158% +$866K ﹤0.01% 4248
2018
Q3 		$752K Sell
7,487
-922
-11% -$69.3K ﹤0.01% 4737
2018
Q2 		$555K Buy
8,409
+887
+12% +$53.9K ﹤0.01% 5029
2018
Q1 		$376K Buy
7,522
+295
+4% +$14.2K ﹤0.01% 5158
2017
Q4 		$350K Buy
7,227
+2,203
+44% +$109K ﹤0.01% 5173
2017
Q3 		$306K Buy
5,024
+1,720
+52% +$98.7K ﹤0.01% 5152
2017
Q2 		$234K Sell
3,304
-891
-21% -$57.7K ﹤0.01% 5256
2017
Q1 		$272K Sell
4,195
-4,889
-54% -$380K ﹤0.01% 5171
2016
Q4 		$854K Buy
9,084
+6,737
+287% +$688K ﹤0.01% 4588
2016
Q3 		$265K Sell
2,347
-193
-8% -$18.7K ﹤0.01% 4879
2016
Q2 		$208K Buy
2,540
+382
+18% +$24.3K ﹤0.01% 4917
2016
Q1 		$106K Buy
2,158
+1,961
+995% +$83.7K ﹤0.01% 5295
2015
Q4 		$9K Sell
197
-7
-3% -$292 ﹤0.01% 6265
2015
Q3 		$9K Sell
204
-5
-2% -$230 ﹤0.01% 6263
2015
Q2 		$10K Sell
209
-72
-26% -$3.07K ﹤0.01% 6298
2015
Q1 		$12K Buy
281
+268
+2,062% +$11.1K ﹤0.01% 6183
2014
Q4 		$1K Sell
13
-3
-19% -$114 ﹤0.01% 6489
2014
Q3 		$1K Buy
+16
New +$851 ﹤0.01% 6496

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM

Morgan Stanley's NERV Position: Q1 2026 in Review

Morgan Stanley increased its Minerva Neurosciences (NERV) stake by 120% in Q1 2026, buying an estimated $76.2K and bringing the position to 24,332 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #5998.

Morgan Stanley first reported a position in NERV in Q3 2014 and has held it in 47 quarters since. The position peaked at $2.71M in Q1 2021. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Morgan Stanley held 24,332 shares of Minerva Neurosciences worth $147K as of Q1 2026.
  • Morgan Stanley bought 13,277 Minerva Neurosciences shares in Q1 2026, an estimated $76.2K.
  • Minerva Neurosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5998 holding.
  • Morgan Stanley first reported a position in Minerva Neurosciences in Q3 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Minerva Neurosciences position peaked at $2.71M in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.